Trial Profile
POL6326 - A Phase I, Open, Single Intravenous Infusion Dose, Pharmacokinetic and Pharmacodynamic Study in Healthy Volunteers Who Are Volunteering as Haematopoietic Stem Cell (HSC) Donors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Balixafortide (Primary)
- Indications Stem cell mobilisation
- Focus Adverse reactions
- Sponsors Polyphor
- 24 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2015 Planned End Date changed from 1 Dec 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
- 02 Jul 2015 Planned primary completion date changed from 1 Sep 2013 to 1 Aug 2015 as reported by ClinicalTrials.gov record.